Notable Labs began by providing tumor screening services to pharmaceutical companies, generating revenue and data to support their drug development efforts.

At Isomorphic Labs, we collaborate with various companies to generate proprietary data, which has proven to be impactful in drug development.

Partnerships with Eli Lilly and Novartis have allowed us to tackle challenging problems in drug design, leading to the discovery of new chemical matter.

Our sister company, Isomorphic Labs, is developing technologies around AlphaFold to design drug compounds that bind to specific parts of protein surfaces, which is crucial for understanding diseases.

Our internal drug design projects focus on immunology and oncology, and we've made significant progress using advanced models.

The ambition at Isomorphic Labs is to develop a drug design engine that can continuously adapt and apply to new challenges across different diseases, fundamentally changing drug discovery.

There's a significant opportunity in generating in vivo data, which is currently limited, to better understand drug interactions in real biological systems, and we're seeing breakthroughs in data-generating technology in biology and chemistry that will significantly impact how we model these fields.

In the next few years, we aim to build a comprehensive database of virtual cells to enhance drug target design and therapeutic success rates.

Personalized medicine, which tailors treatment plans to individual patients based on their specific medical cases, is on the horizon and could significantly improve life expectancy.